Key Takeaways
- Guidance withdrawn, visibility low: Management explicitly pulled near-term growth guidance, citing volatile markets and supply chains that are still not aligned with plan. The earlier implied 18-20% growth for the balance nine months was missed as revenue stayed flat.
- Supply chain is the binding constraint: Stopper shortages, bag line disruptions (running at ~50%), and delayed Lyo installations choked volumes, costing an estimated ₹40-50 crore per quarter in lost heparin sales alone. Improvement began only in the second half of Q2.
- Margins compressed by mix and one-offs: EBITDA margin fell to 33% from 38% YoY, driven by higher freight from airlifting, a ₹7-8 crore biologic CDMO inventory write-off, and ~500 new biosimilar headcounts. Excluding one-offs, the run-rate was ~30.5-31%.
- Competitive intensity is reshaping US returns: New launches, especially in oncology (Pemetrexed, Bortezomib), are seeing first-year margins compress immediately rather than after three years, as too many players crowd in.
- What to watch next quarter: Whether heparin stopper supplies normalize as promised in November, the pace of the ~25 planned US SKU launches, and any stabilization in RoW and India margins as freight costs ease.
Supply Chain Disruptions
- Stopper shortages: Heparin stopper supplies did not start in Q2, costing ~₹40-50 crore per quarter in lost sales. Some stoppers are expected in November, with full normalization targeted by Q1 of next calendar year through a mix of existing and newly qualified suppliers.
- Bag manufacturing constrained: The bag line ran at only ~50% of the quarter due to material shortages, directly capping US volumes. Additional CAPEX is planned because current bag capacity cannot meet US demand.
- Insulin restart delayed: Commercial production of Insulin restarted only in the second half of the quarter, billing ₹11 crore against a normal ₹25-30 crore run rate.
- Lyo capacity tight: Three new Lyophilizers are running at 80% capacity, leaving the company unable to cater to larger CMO contracts.
- Alternate suppliers qualified: For RoW prefilled syringe products, alternate suppliers (beyond BD) have been qualified and supplies initiated with one, helping return those supplies to normalcy.
- Cost of resilience: Qualifying additional suppliers for stoppers, tubing, and filters has added costs over the last few quarters, and management prefers to hold high inventory given the volatile supply situation.
Srinivas Sadu: "Being the market is so volatile and the supplies are not yet 100% in line with our plan, it's very difficult to estimate the near term growth and difficult to comment on future growth or business guidance for short tenure."
US Market: Volume Pressure & Competitive Cycle
- Volume degrowth: US volumes declined 7-8% because the company could not supply certain products and demand for some key products did not return to earlier levels. Prior pipeline inventory built up by customers is still being used up.
- Oncology launches underperformed: Large oncology products like Pemetrexed and Bortezomib did not contribute expected volumes because too many players entered, driving price erosion. These launches were a key reason the implied 18-20% growth did not materialize.
- First-year margin compression: Historically, new launches earned 65-80% contribution margin in year one, settling to 40-50% after three years. Now, intense competition is compressing margins in the first year itself.
- Recovery expectation: Volume degrowth should start recovering from this quarter or next as prior pipeline inventory gets used up. ~25 SKU launches are planned over the next two quarters (9 this quarter, 16 next), against a normal annual cadence of 25-30.
- Cyclical view: Management expects the current intense pricing competition to ease as companies fill capacities and exit, similar to past cycles. FDA auditing activity may also impact competitor sustainability.
Srinivas Sadu: "We have to see whether the competition will stay intact, and how long can they sustain with this pricing what they're offering in the market. Because this is a cycle, we are in that space where we have seen that few years ago, where a lot of companies launched till the capacities get filled up and then they start exiting the market."
Margin Walk
- EBITDA margin fell to 33% from 38% YoY: The decline was driven by higher operating expenses: increased logistic costs from air shipments, one-time expenses, higher power cost, and employee cost from added headcount for the biologics/biosimilar CDMO facility and new commercial lines.
- One-off costs in the quarter: A ₹7-8 crore inventory write-off in the biologic CDMO facility (based on customer feedback on a Drug Substance project) and ~₹4 crore in M&A costs. Excluding these, the quarterly EBITDA margin run-rate would have been ~30.5-31%.
- RoW contribution margin collapsed: Fell from 35% to 25% YoY, mostly due to higher import costs and airlifting because of supply disruption. Under the transfer price model, these costs could not be passed on.
- Canada margin halved: Contribution margin fell from ~88% to 65% due to lower pricing on Bortezomib sales.
- India business squeezed: Sales were lower than expected because import costs rose (dollar appreciation adding to cost) and margins were too low to compete in the domestic market.
- Biosimilar headcount drag: ~500 headcounts were added for the biosimilar business across Pashamylaram and Shamirpet facilities, weighing on margins until revenue starts.
Ravi Shekhar Mitra: "Once the revenue start coming, biosimilar Shamirpet facility, that would negate."
CDMO & Biosimilar Build-Out
- Biologic CDMO progress: Several customer visits were completed during H1 FY23. A few customers have moved to commercial negotiations. The company signed up for a fill-finished clinical batch project and is discussing Drug Substance project commercials.
- Inventory write-off taken: A one-time ₹7-8 crore inventory write-off was taken in the biologic CDMO facility based on customer feedback on Drug Substance project requirements.
- Biosimilar CDMO revenue timeline: Business will start for sure in calendar year 2023, but may not cover 100% of costs initially. Overhead costs (people, utility, consumables) are fully built and will not increase when revenue starts; only direct material will scale with revenue.
- Capacity additions: Manufacturing lines for suspensions and hormones have been installed. A new liquid vial line for hormone suspension products is running R&D batches for complex product filings. One more oncology line was added at Vizag to leverage for CDMO business.
Geographic & Product Diversification
- China: Receiving encouraging feedback, which should help increase the pace of filings over the next year. Two products are expected to receive approval by end of this year (one this quarter, one next quarter), six more expected next year, and six additional filings are planned in FY24.
- RoW normalization: Prefilled syringe product supplies have returned to normalcy after alternate supplier qualification. The GCC region now contributes ~26-27% of RoW revenue with a better margin profile, and additional capacity is coming on track to support continued focus.
- Complex pipeline: Expect another two complex filings during the current fiscal. ANDA filings will further accelerate in the second half of the fiscal year.
- Long-term drivers: Opportunities identified in long-acting injectables, ophthalmic suspensions, pen auto-injectors, and bags, plus new geographies and the biosimilar CDMO space. Management describes the current phase as a consolidation period to streamline supply and add alternate sources.
Srinivas Sadu: "Once in five, six years where we have to consolidate the business, I think we're using that now. But from opportunity... we are pretty confident on the growth in the future because the opportunities are there."
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Heparin stopper normalization | Some stoppers expected in November; full normalization through existing and newly qualified suppliers | Q1 next calendar year |
| US volume recovery | Volume degrowth should start recovering as prior pipeline inventory gets used up | This quarter or next quarter |
| US launches | ~25 SKU launches planned (9 this quarter, 16 next quarter) | Next two quarters |
| China approvals | Two products expected approval (one this quarter, one next quarter); six more next year | By end of this year / next year |
| China filings | Six additional filings planned | FY24 |
| Biosimilar CDMO revenue start | Business will start for sure, but may not cover 100% of costs initially | Calendar year 2023 |
| EBITDA margin run-rate | Excluding one-offs, should be around 30.5-31% on a quarterly basis | Ongoing quarterly basis |
| CAPEX spend | On track to spend ₹300-350 crore | By FY23 year-end |
| Complex filings | Expect another two complex filings | During current fiscal |
Key Metrics
| Metric | Q2 FY23 |
|---|---|
| Revenue from operations | ₹1,044.4 cr, down 3% YoY from ₹1,080.5 cr, up 22% QoQ |
| H1 FY23 revenue from operations | ₹1,901.3 cr, down 15% YoY |
| EBITDA | ₹362.5 cr, down 15% YoY from ₹427.8 cr |
| EBITDA margin | 33%, compared to 38% in Q2 FY22 |
| EBITDA margin excluding other income | 28.5%, or ~30.5% adjusted for one-time items |
| PAT | ₹241.2 cr, down 20% YoY from ₹302.1 cr |
| PAT margin | 22% |
| Gross margin | Stable YoY in Q2 and H1; QoQ decline due to geography and product mix |
| R&D expenditure (excl. capital R&D) | 3.8% of revenue, ₹39.4 cr, up 9% YoY from ₹36.2 cr (3.3% of revenue) |
| Cash flow from operations (quarter) | ₹62.7 cr |
| Cash flow from operations (H1 FY23) | ₹395.6 cr |
| Total cash and bank balances | ₹3,820 cr as of September 2022 |
| CAPEX incurred (H1 FY23) | ₹82.5 cr |
| Core markets revenue share | 72% of revenue, up from 67% in Q2 FY22 |
| Rest of World revenue share | 21% of revenue, same as Q2 FY22 |
| India revenue share | 7% of revenue |
| US profit share | 7% for the quarter; 8% for H1 FY23 and H1 FY22 |
| Revenue from new launches | ~3% of revenue |
| Product SKUs launched | 6 during the quarter |
| ANDA filings completed | 6 during the quarter |
| Total ANDA filings in the US | 322 as of 30th September 2022 |
| Total product registrations globally | 1,586 as of 30th September 2022 |
| US volumes | Degrowth of 7%–8% |
| Rest of World gross margin | 25%, down from 35% in Q2 FY22 |
| Canada contribution margin | 65%, down from ~88% |
| Heparin stopper-related sales loss | ~₹40–50 cr per quarter |
| CDMO non-revenue OPEX at EBITDA level | ₹15 cr for the quarter, plus ₹6–7 cr depreciation |
| One-time inventory write-off (biologic CDMO) | ~₹7–8 cr, ~0.7%–0.8% impact on gross margin |
| M&A cost | ~₹4 cr |
| Headcount added for biosimilar business | ~500 employees |
| Liquid vials capacity utilization | 85%–90% |
| Lyophilizer capacity utilization | ~80% |
| Average cash conversion cycle (H1 FY23) | 231 days, up from 198 days in H1 FY22 |
| ROCE on ex-cash basis (H1 FY23, annualized) | 21% |
| Fixed assets turnover (H1 FY23) | 2.4x, down from 3.4x in H1 FY22 |
| Effective tax rate | ~26% in Q2 and H1 FY23 |
| China filings | 8 products filed; 2 approvals expected by end of CY22, 6 in CY23; 6 more filings planned in FY24 |
| US SKU launches planned (next two quarters) | ~25 (9 in Q3, 16 in Q4); 20 launched in H1 FY23 |